(NESARC), a large national sample of the United States population, was used to assess how 7 many potentially eligible people would fulfil the eligibility criteria. NESARC interviewed 8 more than 43,000 adults aged 18 years and older. We applied a standard set of eligibility 9 criteria representative of smoking cessation clinical trials to all the 4,962 adults with past 12 10 months nicotine dependence, and then to a sub-group of participants motivated to quit 11 (n=4,121). 12
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What this paper adds 1
Clinical trials for treatment of nicotine dependence often exclude sizable parts of the general 2 population with nicotine dependence. This article quantifies the lack of generalizability by 3 using a large representative US general population survey. It was found, that the majority of 4 nicotine dependent subjects would have been excluded from participating in clinical trials. The NESARC used the National Institute on Alcohol Abuse and Alcoholism's Alcohol Use 9
Disorder and Associated Disabilities Interview Schedule DSM-IV version (AUDADIS-IV), a 10 structured diagnostic interview made for non-clinician interviewers [33] . Algorithms were 11 designed to produce diagnoses of nicotine dependence consistent with the final DSM-IV 12 criteria. For example, the "using nicotine to relieve or avoid withdrawal symptoms" criterion 13 was defined by the following 4 items: (1) the use of nicotine as soon as waking up, (2) the use 14 of nicotine after being in a situation in which use was forbidden, (3) the use of nicotine to 15 decrease nicotine withdrawal symptoms, and (4) waking up in the middle of the night to use 16 tobacco [34] . Several studies have documented good to excellent retest reliability [35] . 17
18

Data Analysis 19
Exclusion criteria commonly applied in clinical trials of treatments for nicotine dependence 20 (see below in Clinical Trial Exclusion Criteria) were applied to individuals from the general 21 population to determine the proportion of individuals from the general population with current 22 nicotine dependence according to DSM-IV criteria that would be eligible for the clinical trials. 23
The same criteria were applied to the subset of individuals with current nicotine dependence 24 motivated to quit, examining potential differences in eligibility between motivated and less 25 motivated individuals, using a pattern of analysis described elsewhere [10, 18] . In these 1 studies, Blanco et al. used attempts to quit a substance in the last 12 months as a proxy 2 variable for motivation to quit in the future [10, 18] . 3
The appropriate statistical weight was employed when mentioned to ensure the data were 4
representative of the population. 5
6
Clinical Trial Exclusion Criteria 7 8
We examined eligibility criteria from clinical trials included in a recent meta-analysis 9 comparing the effectiveness of pharmacotherapies for smoking cessation [36] . We collected 10 all eligibility criteria from 54 randomized clinical trials , and ranked them according to 11 their frequency. Criteria included in more than 10% of the studies are listed in Table 1 . The 12 median of the number of eligibility criteria used in a study was 12 (considering not only 13 criteria included in Table 1 but also criteria present in less than 10% of the studies). We thus 14 applied the 12 most frequently used criteria to the NESARC sample. 15 The percentages of individuals excluded by criteria 1, 3, 5, 6, 7, 8, 11 and 12 were estimated 16 from data collected by the AUDADIS-IV. Information to approximate criterion 4 (use of 17 psychotropic medications), criterion 9 (use of bupropion or nicotine replacement therapy) and 18 criterion 10 (history of eating disorder) was not available in the NESARC. 19
Criterion 1 (pregnancy status) was assessed with a single question ("Were you pregnant at any 20 time during the past year?"). 21
The presence of a recent cardiac event (criterion 2) was assessed by series of questions on 22 chest pain, angina pectoris, heart attack, myocardial infarction or any other form of heart 23 disease in the last 12 months, and whether the diagnosis was confirmed by a physician. 24
Criterion 3 ("Smoking 10 cigarettes per day or less on average ") was applied using a 12-25 month time frame (as it is assessed in the NESARC).
Criterion 5 ("Alcohol dependence ") was defined having a diagnosis of alcohol dependence 1 within the last 12 months. 2 Criterion 6 ("Being not motivated to quit smoking ") was assessed by 2 questions: "In you 3 entire life, did you ever, more than once, want to stop or cut down your tobacco use?"), and 4 "Did this happen in the last 12 months?". Participants who respond positively to both 5 questions were classified as being motivated to quit smoking. Other participants were 6 classified as being not motivated to quit smoking. This assessment is therefore at variance 7 with standard questions about motivation in research trials, who usually asked whether 8 participants want to cut down/attempt to stop in the future rather than if they have done so in 9 the past. 10
Criterion 7 ("Dependence to other drugs") was defined having a diagnosis of dependence to 11 an illicit substance (either sedatives, tranquilizers, opiates, stimulants, hallucinogens, 12 cannabis, cocaine (including crack cocaine), inhalants/solvents, heroin, or other drugs) within 13 the last 12 months. 14 Criterion 8 ("Having a current depression") was assessed using the criteria for Major 15 Depressive Disorder within the last 12 months. 16
Criterion 11 ("Having a current psychosis") was assessed by 2 questions: "Did a doctor or 17 other health professional ever diagnose you with schizophrenia or psychotic illness or 18 episode?". Participants who respond positively to this were classified as having "psychosis". 19
Participants with a lifetime history of mania were classified as having a bipolar disorder 20 (Criterion 12). We choose to consider only bipolar type I disorder because hypomania, the 21 hallmark of bipolar type II disorder, is a more subtle form of the disorder and therefore not 22 likely to be screened in routine in eligibility assessments of clinical trials for nicotine 23 dependent individuals. For the same reason, we considered participants as having bipolar 24 disorder if they had a history of mania even if manic episodes were induced by a substance oran illness, and did not restricted our analysis to independent bipolar disorders. As a control, 1
we did a sensitivity analysis to examine how the results would change if (i) substance and 2 illness induced mania were ruled out, and (ii) if bipolar type II disorder was also included in 3 the eligibility criteria (with substance and illness induced disorders being ruled out). 4
Analysis Plan 6
We first determined the number and percentage of nicotine dependent participants of the 7 NESARC who would be excluded by individually applying each of the 12 most frequent 8 eligibility criteria reported previously. . Because individuals might have been excluded by 9 more than 1 criterion, we also calculated the overall percentage of subjects who would have 10 been excluded by the simultaneous application of all the measurable criteria. We conducted 11 these analyses for all individuals with a current DSM-IV diagnosis of nicotine dependence 12 The percentage of subjects excluded by at least one criterion was 65.89% among respondents 21 who met DSM-IV criteria for nicotine dependence and 58.60% of those motivated to quit 22 smoking in the past year (Table 2 ) 23 The percentage of respondents excluded due to the application of a single criterion ranged 24 from 2.14% (lifetime diagnosis of psychosis) to 32.02% (smoking less than 10 cigarettes per 25 day) in the overall sample of respondents with nicotine dependence, and 1.95% (lifetime 1 diagnosis of psychosis) to 33.79% (smoking less than 10 cigarettes per day) among those 2 motivated to quit smoking. 3 4 For the overall sample, smoking 10 cigarettes per day or less and lacking motivation to quit 5 were the two criteria including the highest percentage of individuals. For the treatment-6 seeking sample, having a current depression and smoking 10 cigarettes per day or less were 7 the criteria comprising the greatest percentage of individuals who would not be eligible. 8
Current alcohol dependence and a history of bipolar disorder also excluded a notable 9
proportion of individuals in both samples (Table 2) . 10 A history of bipolar disorder (type I) was present in 10.33 % of the participants with nicotine 11 dependence (CI 95%: 8.16-10.50). As a control, ruling out illness-and substance-induced 12 mania only slightly decreased to 9.26% the percentage of participants excluded because of 13 this criteria (CI 95%:8.16-10.50). When bipolar type II disorder was also included in this 14 eligibility criteria (substance-and illness-induced disorder still ruled out), the percentage of 15 participants excluded because of this criteria raised to 14.70% (95%CI: 13.55-15.93). The 16 overall exclusion rate was 65.58% when considering bipolar I disorder after ruling out illness 17 and substance induced mania, and 66.8% when considering bipolar I and II after ruling out 18 illness and substance induced mania, compared to an overall exclusion rate of 64.13% when 19 considering only bipolar I disorder even if manic episodes were induced by a substance or an 20
illness. This suggests that the criteria used to define bipolar disorder have little or no impact 21 on the overall inclusion rate. 22
More than 6 out of ten respondents from the full nicotine dependent sample and more than 23 half of the subsample of individuals motivated to quit smoking would have been excluded by 24 one or more of the study criteria. A second restriction is that 3 of the 12 exclusion criteria initially included could not be 25 operationalized in our study, because the relevant information was not assessed in theNESARC sample, including (1) participants currently taking a psychotropic medication, (2) 1 participants "currently taking Bupropion or nicotine replacement therapy", and (3) having an 2 eating disorder,. This may theoretically lead to an underestimation of the proportion of 3 patients excluded in clinical trials. However, these criteria are rarely met in the general 4 population. For example, the estimated percentage of smokers in Australia who used 5 bupropion in a year was only 3.6% in 2005 [94] . Eating disorders have a low prevalence, 6 affecting less than 4.5% [95] of the general population. While an investigation of the impact 7 of these exclusion criteria on the generalizability of clinical trials is required in a future study, 8 they are not likely to exclude a significant proportion of smokers. 9
A third limitation is that the NESARC sample included only individuals aged 18 years or 10 older. Information was unavailable for adolescents, who may be have a lower level of 11 comorbidities, and may therefore be more likely to be eligible for clinical trials. 12 Some of the criteria have been implemented for safety reasons (e.g pregnancy, potential 13 interaction with psychotropic drugs or with alcohol) while some other may contribute to 14 stigmatize a significant proportion of the population (e.g having a history of substance abuse 15 with no use within the last 12 months should not be considered as valid exclusion criteria in a 16 clinical trial). 17
The exclusion of participant with alcohol dependence is particularly damageable, since 18 nicotine dependence is a major issue in alcohol-dependent patients. For example, smokers 19 with a lifetime history of alcohol dependence are more likely to die of smoking-related 20 diseases rather than from alcohol-related diseases [96] . Moreover, alcohol-dependent subjects 21 suffering from nicotine dependence have a higher prevalence of nearly all psychiatric and 22 addictive disorders [97], making treatment for smoking cessation in this specific population a 23 unmet need.
In summary, we found that the current criteria of eligibility applied in clinical trial involving 1 nicotine dependent individuals are highly restrictive, and exclude a majority of participants, 2 thus limiting the generalizability of their findings. Particularly, our findings suggested that (1) 3 individuals smoking few cigarettes in a day or (2) having a current or past history of mood 4 disorders (major depressive disorder or bipolar disorder) are underrepresented in clinical 5 trials. These two related groups should be the focus of further investigations. 
